TLR3下调是肝癌发生过程中逃避凋亡的机制
研究探讨TLR3触发的凋亡在肝细胞癌(HCC)细胞中的作用,分析人及小鼠HCC细胞系和手术切除的原发性人HCC组织。TLR3在肿瘤中表达低于配对非肿瘤组织,可预测术后无复发生存期缩短,其缺失保护转化肝细胞免于直接凋亡并加速肝癌发生。
要点
- TLR3在原发性HCC肿瘤中mRNA和蛋白水平均低于配对非肿瘤组织。
- TLR3低表达预测手术切除后无复发生存期缩短(单因素HR 1.79;多因素HR 1.73)。
- TLR3缺失伴癌前肝细胞凋亡率降低并加速肝癌发生,不改变肿瘤免疫浸润。
核心结论
- TLR3下调保护转化肝细胞免于直接TLR3触发的凋亡,从而促进肝癌发生和不良患者结局。
研究设计与样本
- 使用定量逆转录PCR、western blotting、免疫组化和比较基因组杂交分析人和小鼠HCC细胞系及手术切除的原发性人HCC,并在HCC细胞和转基因小鼠HCC模型中进行功能分析。
主要发现
- 原发性HCC肿瘤较配对非肿瘤组织在mRNA和蛋白水平均显示TLR3表达较低。
- TLR3低表达预测手术切除后无复发生存期缩短:单因素分析HR 1.79(95%CI 1.04-3.06;p=0.03),多因素分析HR 1.73(95%CI 1.01-2.97;p=0.04)。
- 免疫组化证实人和小鼠原发性HCC细胞中TLR3频繁下调。
- 分析的6种人HCC细胞系均不表达TLR3,慢病毒转导异位表达TLR3不仅恢复炎症反应还使细胞对TLR3触发的凋亡敏感。
- 在转基因小鼠HCC模型中,TLR3表达缺失伴随癌前肝细胞凋亡率降低和肝癌发生加速,而不改变肿瘤免疫浸润。
临床怎么用
- TLR3可能成为TLR3阳性HCC的有前景的治疗靶点。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Low levels of toll-like receptor 3 (TLR3) in patients with hepatocellular carcinoma (HCC) are associated with poor prognosis, primarily owing to the loss of inflammatory signaling and subsequent lack of immune cell recruitment to the liver. Herein, we explore the role of TLR3-triggered apoptosis in HCC cells. METHODS: Quantitative reverse transcription PCR, western blotting, immunohistochemistry and comparative genomic hybridization were used to analyze human and mouse HCC cell lines, as well as surgically resected primary human HCCs, and to study the impact of TLR3 expression on patient outcomes. Functional analyses were performed in HCC cells, following the restoration of TLR3 by lentiviral transduction. The role of TLR3-triggered apoptosis in HCC was analyzed in vivo in a transgenic mouse model of HCC. RESULTS: Lower expression of TLR3 in tumor compared to non-tumor matched tissue was observed at both mRNA and protein levels in primary HCC, and was predictive of shorter recurrence-free survival after surgical resection in both univariate (hazard ratio [HR] 1.79; 95% CI 1.04-3.06; p = 0.03) and multivariate analyses (HR 1.73; CI 1.01-2.97; p = 0.04). Immunohistochemistry confirmed frequent downregulation of TLR3 in human and mouse primary HCC cells. None of the 6 human HCC cell lines analyzed expressed TLR3, and ectopic expression of TLR3 following lentiviral transduction not only restored the inflammatory response but also sensitized cells to TLR3-triggered apoptosis. Lastly, in the transgenic mouse model of HCC, absence of TLR3 expression was accompanied by a lower rate of preneoplastic hepatocyte apoptosis and accelerated hepatocarcinogenesis without altering the tumor immune infiltrate. CONCLUSION: Downregulation of TLR3 protects transforming hepatocytes from direct TLR3-triggered apoptosis, thereby contributing to hepatocarcinogenesis and poor patient outcome. LAY SUMMARY: Hepatocellular carcinoma (HCC) is a heterogeneous disease associated with a poor prognosis. In patients with HCC, TLR3 downregulation is associated with reduced survival. Herein, we show that the absence of TLR3 is associated with a lower rate of apoptosis, and subsequently more rapid hepatocarcinogenesis, without any change to the immune infiltrate in the liver. Therefore, the poor prognosis associated with low TLR3 expression in HCC is likely linked to tumors ability to escape apoptosis. TLR3 may become a promising therapeutic target in TLR3-positive HCC.
引用
- Bonnin M, Fares N, Testoni B, et al. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. J Hepatol. 2019. PMID: 31220470. doi:10.1016/j.jhep.2019.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。